Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20145796 | 0.81 | ALOX5 (0.49) | ALDH1A1KDM4ELMNANPC1TDP1 | |
| SCHEMBL22240437 | 0.81 | ALOX5 (0.49) | ALDH1A1KDM4ELMNANPC1TDP1 | |
| SCHEMBL8270258 | 0.81 | ALOX5 (0.49) | ALDH1A1KDM4ELMNANPC1TDP1 | |
| SCHEMBL25668462 | 0.78 | ALDH1A1 (0.41) | ALDH1A1HPGDKDM4ELMNAHSD17B10 | |
| SCHEMBL3861132 | 0.77 | MAPT (0.41) | ALDH1A1HPGDLMNATDP1 | |
| SCHEMBL10305737 | 0.76 | RECQL (0.44) | ALDH1A1HPGDKDM4ELMNAHSD17B10 | |
| SCHEMBL22240503 | 0.75 | TAAR1 (0.38) | ALDH1A1HPGDKDM4ELMNATDP1 | |
| SCHEMBL1044302 | 0.68 | CYP2D6 (0.49) | ALDH1A1KDM4ELMNANPC1RECQL | |
| SCHEMBL6725960 | 0.68 | CYP2D6 (0.49) | ALDH1A1KDM4ELMNANPC1RECQL | |
| SCHEMBL6719047 | 0.68 | CYP2D6 (0.46) | KDM4ELMNAHSD17B10NPC1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190047986-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-02-14 | — | — | US | disclosed |
| US-9944622-B2 | Pyrimidinyl tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047986-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | ALDH1A1 3713/4885HPGD 3714/4885KDM4E 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.